Moreover, similar analyses in two tauopathy mouse models (P301S and P301L) suggest that tau aggregation in mice is primarily driven by tau hyperphosphorylation, characteristic of early-stage AD, while other modifications in late-stage human AD (e.g., ubiquitination and acetylation) are absent in these models [117]. This evidence concerns the gene MAPT and Alzheimer disease.